NRAS mutation renders ovarian cancer cells vulnerable to MEK inhibitor trametinib
Engineered ovarian cancer cell models carrying an activating NRAS mutation showed heightened sensitivity to the MEK inhibitor trametinib, suggesting a ...
Engineered ovarian cancer cell models carrying an activating NRAS mutation showed heightened sensitivity to the MEK inhibitor trametinib, suggesting a ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine